Debt-to-equity of Immunovant, Inc. from 30 Sep 2019 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Immunovant, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 31 Dec 2025.
  • Immunovant, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 8.9%, a 24% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Immunovant, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 8.9% -2.7% -24% 31 Dec 2025
Q3 2025 12% +3.2% +38% 30 Sep 2025
Q2 2025 12% +4.2% +53% 30 Jun 2025
Q1 2025 12% +2.8% +30% 31 Mar 2025
Q4 2024 12% +1.2% +11% 31 Dec 2024
Q3 2024 8.4% -4.9% -37% 30 Sep 2024
Q2 2024 7.9% -3.5% -31% 30 Jun 2024
Q1 2024 9.3% +0.66% +7.6% 31 Mar 2024
Q4 2023 10% +2.2% +27% 31 Dec 2023
Q3 2023 13% +5.6% +74% 30 Sep 2023
Q2 2023 11% +4.5% +64% 30 Jun 2023
Q1 2023 8.7% +1.4% +19% 31 Mar 2023
Q4 2022 8.3% +2% +33% 31 Dec 2022
Q3 2022 7.6% +2.2% +41% 30 Sep 2022
Q2 2022 7% +2.2% +45% 30 Jun 2022
Q1 2022 7.3% +2.1% +41% 31 Mar 2022
Q4 2021 6.2% +0.27% +4.6% 31 Dec 2021
Q3 2021 5.4% -2% -27% 30 Sep 2021
Q2 2021 4.8% -7.8% -62% 30 Jun 2021
Q1 2021 5.2% -17% -77% 31 Mar 2021
Q4 2020 6% -30% -83% 31 Dec 2020
Q3 2020 7.5% +84% 30 Sep 2020
Q2 2020 13% 30 Jun 2020
Q1 2020 23% 31 Mar 2020
Q4 2019 35% 31 Dec 2019
Q3 2019 -76% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.